Cellares and Cabaletta Bio secure FDA milestone for automated CAR T production
Cellares and Cabaletta Bio (NASDAQ:CABA) announced a landmark regulatory achievement Monday, with the FDA clearing an Investigational New Drug (IND) Amendment to manufacture the autoimmune-focused CAR T therapy, rese-cel, using Cellares’ fully automated platforms.





-640x358.jpg&w=3840&q=75)




